Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Lansoprazole. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel vanadium-catalyzed asymmetric oxidation for S-omeprazole. High purity, scalable process reducing costs for pharmaceutical supply chains globally.
Patent CN102180865B details a green oxidation method for Lansoprazole using composite metal oxides, offering high purity and reduced environmental impact for pharmaceutical manufacturing.
Patent CN101012141B reveals catalytic oxidation for high-purity PPIs. Enables cost reduction in pharmaceutical intermediates manufacturing with scalable routes.
Patent CN107365300A details a novel salt formation technique for Lansoprazole. This method ensures high purity and yield while offering substantial supply chain and cost advantages for global buyers.
Patent CN104387368A details a novel enantioselective oxidation for R-Lansoprazole. Achieve 99.5% ee with reduced impurities and scalable manufacturing processes.
Novel patent CN106543146A offers efficient R-lansoprazole preparation. Enhances supply chain reliability and reduces manufacturing costs for global pharmaceutical partners.
Patent CN1214027C details a novel route for PPI intermediates using N-oxide activation, offering significant cost reduction in API manufacturing and improved supply chain reliability.
Patent CN102731478A details a high-yield asymmetric oxidation route for Dexlansoprazole intermediates, offering superior optical purity and scalable manufacturing capabilities for global supply chains.
Patent CN102731478A details a high-yield asymmetric oxidation route for Dexlansoprazole intermediates, offering superior optical purity and scalable manufacturing solutions.
Patent CN105399728B reveals high-yield R-lansoprazole production. Enhances supply chain reliability and reduces manufacturing costs for pharmaceutical partners globally.
Advanced one-pot synthesis of Lansoprazole via patent CN112707889A. Achieves >99.9% purity and >92% yield with reduced waste, offering a reliable lansoprazole intermediate supplier solution.
Patent CN104610226A reveals a novel asymmetric oxidation method for dexlansoprazole intermediates, offering high purity and scalable supply chain advantages for global pharmaceutical manufacturers.
Novel catalytic oxidation process for S-omeprazole and analogs ensures high optical purity and simplified production workflow for global supply chains.
Patent CN106866630B reveals high-yield asymmetric oxidation for R-lansoprazole. Reduces impurities and enhances commercial scalability for pharmaceutical supply chains globally.
Patent CN104447696B details improved Lansoprazole synthesis yielding 98% purity. Enhances supply chain reliability and cost reduction in pharmaceutical intermediate manufacturing.
Novel enantioselective oxidation method using titanium-tartrate catalysts offers high purity and cost efficiency for proton pump inhibitor manufacturing.
Novel purification method for Dexlansoprazole anhydrous substance ensures 99.9% purity. Reduces peroxidation impurities significantly for reliable pharmaceutical intermediate supply chains.
Patent CN102977076A reveals a high-purity R-lansoprazole synthesis using chiral titanium catalysis. Discover cost-effective manufacturing insights for pharmaceutical supply chains.
Patent CN102558151A reveals a green asymmetric oxidation method for proton pump inhibitors, offering high enantioselectivity and reduced heavy metal contamination for reliable API intermediate suppliers.
Patent CN102225909B reveals a one-step synthesis for lansoprazole intermediates, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturers.